A fixed-duration regimen of AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for previously untreated chronic lymphocytic leukaemia (CLL).  The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use and was based on […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!